Latest filing published 08 Apr 2024 for NGM Biopharmaceuticals INC.
Filings by Jean-Frederic Viret span 2 companies, the busiest being Coherus Oncology, Inc. and NGM Biopharmaceuticals Inc. Over a trading history stretching from 28 March 2016 to 5 April 2024, the count stands at 57 filings.
No open-market purchase appears, only 29 sales worth €2.5M. Besides market trades, the filings include 8 share grants and 19 option exercises.
On 8 April 2024 came the latest disclosure, a transaction in NGM Biopharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 57 declarations